Seeing path for cholesterol-lowering program, Forbion launches start-up to house former Dezima molecule

Five years after reaping a strong return from cholesterol-lowering molecule obicetrapib, Forbion is again investing in the program based on a belief it can serve some dyslipidemia patients where others in its class fell short.

This time, the firm has created a start-up to reacquire the CETP inhibitor and take it through pivotal studies following Amgen’s decision to halt its development. A Phase III program is due to begin next year...